secwatch.observer — SEC 8-K summary
======================================

Issuer:     ESSA Pharma Inc. (—)
CIK:        0001633932
Form:       8-K
Filed at:   2025-10-09T23:59:59+00:00
Accession:  0001104659-25-098078
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ESSA Pharma acquired by XenoTherapeutics for $0.1242/share plus CVR; shares to be delisted
--------------------------------------------------------------------------------

- Shareholders received US$0.1242 per common share plus one CVR per share worth up to US$0.14.
- Aggregate potential CVR payment of US$6.7 million dependent on contingent liabilities.
- Final court order from Supreme Court of British Columbia obtained on October 7, 2025.
- All directors resigned; Jon Adkins (Xeno Acquisition Corp.) becomes sole director.
- ESSA requested Nasdaq delisting effective October 10, 2025; Form 15 to terminate registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1633932/000110465925098078/0001104659-25-098078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1633932/000110465925098078/tm2528270d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-098078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer